Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 1, 2014, Pages 78-81

  Gulick, Roy M ^a   Fatkenheuer, Gerd ^b   Burnside, Robert ^c   Hardy, W David ^d   Nelson, Mark R ^e   Goodrich, James ^f   Mukwaya, Geoffrey ^c   Portsmouth, Simon ^g   Heera, Jayvant R ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f VIIV HEALTHCARE   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; CCR5 antagonist; HIV; Maraviroc; Safety; Treatment experienced patients

Indexed keywords

MARAVIROC; PLACEBO; VIRUS RNA;

ADULT; ANUS CANCER; ARTICLE; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; LEUKEMIA; LIVER FAILURE; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SURVIVAL;

ADULT; CYCLOHEXANES; DOUBLE-BLIND METHOD; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; SURVIVAL ANALYSIS; TIME FACTORS; TRIAZOLES;

EID: 84893732996     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a7a97a     Document Type: Article

References (15)

1. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
2. Caldwell DJ, Evans JD. Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection. Expert Opin Pharmacother. 2008;9: 3231-3242.
3. Currier J, Lazzarin A, Sloan L, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir Ther. 2008;13:297-306.
4. Wilkin TJ, Su Z, Krambrink A, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010;54:470-476.
5. Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J Infect. 2012;65:326-335.
6. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
7. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and. J Acquir Immune Defic Syndr. 2010;55:558-564.
8. Rockstroh J, deJesus E, Saag M, et al. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1-infected patients: final 5-year double-blind results from STARTMRK [abstract LBPE19]. Geneva, Switzerland, International AIDS Society. In: Program and Abstracts of the XIX International AIDS Conference (AIDS 2012); 2012; Washington, D.C.
9. Ayoub A, Alston S, Goodrich J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 2010;24:2743-2750.
10. Walmsley S, Campo R, Goodrich J, et al. Low risk of malignancy with maraviroc in treatment-experienced (TE) and treatment-naïve (TN) patients across the maraviroc clinical development program [abstract TuPE0157]. Geneva, Switzerland, International AIDS Society. Program and Abstracts of the XVIII International AIDS Conference; 2010; Vienna, Austria.
11. Steigbigel RT, Cooper D, Eron J, et al. 96-Week Results from BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART with Triple-class-resistant HIV [abstract 571b]. Alexandria, VA: CROI. Programs and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
12. Portsmouth S, Burnside R, Lazzarin A, et al. Incidence of Ischemic Cardiovascular Events in the Maraviroc Clinical Development Program [abstract P65]. Cheshire, UK: Tenth International Congress on Drug Therapy in HIV Infection. Program and Abstracts of the 10th International Congress on Drug Therapy in HIV Infection; 2010; Glasgow, Scotland.
13. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-330.
14. Klein D, Hurley L, Quesenberry C, et al. Hospitalizations for CHD and MI Among Northern California HIV+ and HIV-Men: Changes in Practice and Framingham Risk Scores [abstract 737]. Alexandria, VA: Foundation for Retrovirology and Human Health. In: Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, C.O.
15. Lazzarin A, Lalezari J, Reynes J, et al. Maraviroc (MVC) expanded access program (EAP): outcomes in treatment-experienced patients receiving MVC with or without other novel agents [abstract H-209]. Washington, DC: American Society for Microbiology. In: Final Program of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010; Boston, M.A.